SCHEMBL1220135

SCHEMBL1220135

C=CN1CCCC1.[H+]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23540 0.96
SCHEMBL8334582 0.93
SCHEMBL8897524 0.93 CA1 (0.32)
Fluoride SCHEMBL3504847 0.93
SCHEMBL36141 0.93
Fluoride SCHEMBL3504842 0.93
Hydrochloric Acid SCHEMBL13278201 0.93
Iodide SCHEMBL10613632 0.93
SCHEMBL22043013 0.93 CA1 (0.32)
SCHEMBL9568053 0.93 CA1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1997009965-A1 A NON-IRRITATING SKIN AND HAIR REJUVENATING COMPOSITION HAVING A pH BETWEEN 1 AND 6.5 ISP INVESTMENTS INC. (US) 1997-03-20 WO claimed
US-5605685-A CROSSLINKED N-VINYL LACTAM HYDROGEL AND ONE OF PYRUVIC ACID, MONO- AND POLYCARBOXYLATED HYDROCARBONS OPTIONALLY SUBSTITUTED WITH HYDROXY, AND AN AMMONIUM OR ALKALI METAL SALT OF THE PRECEDING COMPOUNDS ISP INVESTMENTS INC. (US) 1997-02-25 US claimed
US-20240092731-A1 CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF ULTRAGENYX PHARMACEUTICAL INC. 2024-03-21 US disclosed
EP-3771709-B1 CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF FARMINGTON PHARMA DEV (US) 2024-03-20 EP disclosed
CN-117179817-A System and method with expandable material disposed on transducer of ultrasound imaging system 波士顿科学国际有限公司 2023-12-08 CN disclosed
US-11753369-B2 Creatine prodrugs, compositions and methods of use thereof ULTRAGENYX PHARMACEUTICAL INC. (US) 2023-09-12 US disclosed
CN-111417620-B Creatine prodrugs, compositions thereof, and methods of use 奥特吉尼克斯制药公司 2023-08-25 CN disclosed
EP-3569623-B1 VINYL-LACTAM-BASED HYDROGEL COATINGS CONSEJO SUPERIOR INVESTIGACION (ES) 2023-08-09 EP disclosed
US-11407722-B2 Creatine prodrugs, compositions and methods of use thereof Farmington Pharma Development (US) 2022-08-09 US disclosed
US-20220227703-A1 CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF ULTRAGENYX PHARMACEUTICAL INC. 2022-07-21 US disclosed
US-11332438-B2 Creatine prodrugs, compositions and methods of use thereof ULTRAGENYX PHARMACEUTICAL INC. (US) 2022-05-17 US disclosed
EP-1140027-A1 DOSAGE FORMS COMPRISING POROUS PARTICLES Alza Corporation (US) 2001-10-10 EP disclosed
US-6120803-A Prolonged release active agent dosage form adapted for gastric retention ALZA CORPORATION (US) 2000-09-19 US disclosed
WO-2000038650-A1 GASTRIC RETENTION DOSAGE FORM HAVING MULTIPLE LAYERS ALZA CORPORATION (US) 2000-07-06 WO disclosed
WO-2000038655-A1 DOSAGE FORMS COMPRISING POROUS PARTICLES ALZA CORPORATION (US) 2000-07-06 WO disclosed
EP-1003476-A1 PROLONGED RELEASE ACTIVE AGENT DOSAGE FORM ADAPTED FOR GASTRIC RETENTION ALZA CORPORATION (US) 2000-05-31 EP disclosed
WO-1999007342-A1 PROLONGED RELEASE ACTIVE AGENT DOSAGE FORM ADAPTED FOR GASTRIC RETENTION ALZA CORPORATION (US) 1999-02-18 WO disclosed
EP-0372020-A4 PROCESS FOR COATING POLYMER SURFACES AND COATED PRODUCTS PRODUCED USING SUCH PROCESS 1991-11-21 EP disclosed
EP-0372020-A1 PROCESS FOR COATING POLYMER SURFACES AND COATED PRODUCTS PRODUCED USING SUCH PROCESS Bristol-Myers Company (US) 1990-06-13 EP disclosed
WO-1989007521-A1 PROCESS FOR COATING POLYMER SURFACES AND COATED PRODUCTS PRODUCED USING SUCH PROCESS BRISTOL-MYERS COMPANY (US) 1989-08-24 WO disclosed